Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Chen Hong, Jianping Wei, Tao Zhou, Xia Wang & Jing Cai. (2022) FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib. OncoTargets and Therapy 15, pages 651-657.
Read now
Read now
Qiuxia Zhong & Zhihua Liu. (2021) Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study. Cancer Management and Research 13, pages 4115-4128.
Read now
Read now
Li Li, Wei Liu, Yuchao Wang, Qian Zhang, Chuanzhen Chi, Qiaohong Bai, Chunhua Xu & Rusong Yang. (2021) Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer. Journal of Chemotherapy 33:7, pages 492-498.
Read now
Read now
Jian-De Cheng, Li-Xun Chai, Zhi-Ping Zhao, Yan-Yan Hao & Shuo Li. (2020) Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Management and Research 12, pages 5641-5650.
Read now
Read now
Kun Zhang, Xiya Ma, Hongjun Gao, Hong Wang, Haifeng Qin, Shaoxing Yang & Xiaoqing Liu. (2020) Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study. Cancer Management and Research 12, pages 3409-3417.
Read now
Read now
Articles from other publishers (16)
V. Meenakumari, J. Mangaiyarkkarasi, R. Premkumar, R. Mohamed Asath, A. Milton Franklin Benial & N. Thenmozhi. (2024) Spectroscopic Characterization, Quantum Chemical and Molecular Docking Investigations on Methyl Indole-3-Carboxylate: A Potent Cervical Cancer Drug. Journal of Molecular Structure, pages 137711.
Crossref
Crossref
Jingyi Wang, Xiaoqing Li, Juan Zhou, Dan Qiu, Mengyao Zhang, Lan Sun & Shengwen Calvin Li. (2023) Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report. Frontiers in Oncology 13.
Crossref
Crossref
Shu Zhao, Peng Wang, Fan Yin, Junjie Wu, Yuying Wang, Peng Li, Yong Zhang, Jing Yang, Xueguang Guo, Dong Zhang & Peng Song. (2022) Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib. Tumori Journal 109:2, pages 186-196.
Crossref
Crossref
Fen Wang, Feng Jin, Boran Cheng, Yue Zhang, Qing Zhou & Shubin Wang. (2021) The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 148:7, pages 1721-1735.
Crossref
Crossref
Ying Cheng, Qiming Wang, Kai Li, Jianhua Shi, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang, Haifeng Qin & Xiaoling Li. (2021) Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine 11:4, pages 1081-1087.
Crossref
Crossref
Jiaojiao Suo, Yu Sun, Yan Fu, Weigang Xiu, Xuanwei Zhang, Yan Wang & Jiang Zhu. (2021) A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy. Frontiers in Oncology 11.
Crossref
Crossref
Jing Cai, Shan ZhouYuxi LuoAnwen Liu. (2021) Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. Medicine 100:51, pages e28126.
Crossref
Crossref
Mohammed Hawash, Deniz Cansen Kahraman, Sezen Guntekin Ergun, Rengul Cetin-Atalay & Sultan Nacak Baytas. (2021) Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines. BMC Chemistry 15:1.
Crossref
Crossref
Saikat Mitra, Shajuthi Rahman Prova, Sifat Ara Sultana, Rajib Das, Firzan Nainu, Talha Bin Emran, Abu Montakim Tareq, Md. Sahab Uddin, Ali M. Alqahtani, Kuldeep Dhama & Jesus Simal-Gandara. (2021) Therapeutic potential of indole alkaloids in respiratory diseases: A comprehensive review. Phytomedicine 90, pages 153649.
Crossref
Crossref
Xiangyu Zhang, Liang Zeng, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Xinru Mao, Ren’an Jin, Yu Zeng, Qinglin Li, Jianbo Wang, Yang Li, Yongchang Zhang & Nong Yang. (2021) Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunology, Immunotherapy 70:9, pages 2517-2528.
Crossref
Crossref
Qi Xiong, Boyu Qin, Lingli Xin, Bo Yang, Qi Song, Yu Wang, Sujie Zhang & Yi Hu. (2021) Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Xiufeng Cong, Jun Chen & Ran Xu. (2021) Tumor-Acidity Responsive Polymeric Nanoparticles for Targeting Delivery of Angiogenesis Inhibitor for Enhanced Antitumor Efficacy With Decreased Toxicity. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Crossref
Lu Guo, Luyao Zhang, Yan Guan, Yan Li, Chufeng Zhang & Qisen Guo. (2021)
In vitro
studies of
H520
cell cycle and apoptosis by anlotinib combined with radiotherapy
. Thoracic Cancer 12:5, pages 593-602.
Crossref
Crossref
Wei Zhou, Yongping Gao, Yaqi Tong, Qingjun Wu, Yunzhi Zhou & Yanming Li. (2021) Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma. Pharmacological Research 164, pages 105392.
Crossref
Crossref
Xiaohua Zhang, Li Peng, Qing Xie, Qingjing Wu & Xia Sheng. (2020) Hypertensive Retinopathy Secondary to Anlotinib Treatment. Frontiers in Pharmacology 11.
Crossref
Crossref
Jyothi Dhuguru & Rachid Skouta. (2020) Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents. Molecules 25:7, pages 1615.
Crossref
Crossref